GO:0019373 epoxygenase P450 pathway: Arachidonic Acid Metabolism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019373 (epoxygenase P450 pathway) describes the cytochrome P450-mediated conversion of arachidonic acid into epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids (DHETs).
• The pathway is initiated by CYP epoxygenases, primarily CYP2C and CYP2J subfamily enzymes, which insert an oxygen atom into arachidonic acid to form four regioisomeric EETs.
• EETs are subsequently hydrolyzed by soluble epoxide hydrolase (sEH/EPHX2) to less active DHETs, a step that regulates the biological half-life of these lipid mediators.
• Genetic variation in CYP epoxygenase genes and EPHX2 has been associated with cardiovascular disease risk, hypertension, and renal function.
• The pathway is implicated in cancer biology, where epoxygenase products can influence tumor growth, metastasis, and chemotherapy response.
• EETs exhibit neuroprotective and anti-inflammatory effects, making the pathway a target for neurological and cardiovascular therapeutic development.
Description
The epoxygenase P450 pathway (GO:0019373) is a metabolic route through which arachidonic acid, a polyunsaturated fatty acid released from membrane phospholipids, is converted into bioactive lipid mediators known as epoxyeicosatrienoic acids (EETs) and their downstream dihydroxyeicosatrienoic acids (DHETs). This pathway is catalyzed by cytochrome P450 enzymes, predominantly of the CYP2C and CYP2J families, which function as epoxygenases to introduce an epoxide group into the arachidonic acid backbone. The resulting EETs are potent signaling molecules involved in vascular tone regulation, inflammation, and cellular proliferation. Researchers study this pathway because it represents a critical node linking lipid metabolism to cardiovascular, renal, and neurological physiology and disease. The balance between EET production and degradation by soluble epoxide hydrolase (sEH) determines the local concentration of these mediators and their biological effects.
epoxygenase P450 pathway At A Glance
| GO ID | GO:0019373 |
|---|---|
| GO term | epoxygenase P450 pathway |
| Ontology | biological_process |
| Synonym | None |
| Major function | Conversion of arachidonic acid to epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids (DHETs) |
| Key enzymes | Cytochrome P450 epoxygenases (CYP2C, CYP2J subfamilies) and soluble epoxide hydrolase (EPHX2) |
| Substrates | Arachidonic acid |
| Products | Epoxyeicosatrienoic acids (EETs), dihydroxyeicosatrienoic acids (DHETs) |
| Associated diseases | Cardiovascular disease, hypertension, cancer, neuroprotection |
What Is GO:0019373?
According to the Gene Ontology, GO:0019373 (epoxygenase P450 pathway) is defined as the chemical reactions and pathways by which arachidonic acid is converted to other compounds including epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids. In essence, it encompasses the enzymatic steps that transform arachidonic acid into epoxygenated metabolites and their subsequent hydrolysis products, primarily mediated by cytochrome P450 epoxygenases and soluble epoxide hydrolase.
Why Is epoxygenase P450 pathway Important in Cell Biology?
The epoxygenase P450 pathway is critically important because it generates lipid mediators that regulate vascular tone, inflammation, and cellular survival, and its dysregulation has been linked to major human diseases including hypertension, cardiovascular disorders, and cancer. Understanding this pathway provides insights into how genetic and pharmacological modulation of cytochrome P450 epoxygenases and soluble epoxide hydrolase can influence disease progression and treatment outcomes.
• Regulates vascular tone and blood pressure through EET-mediated vasodilation.
• Modulates inflammatory responses and endothelial function.
• Influences cancer cell proliferation, metastasis, and chemotherapy sensitivity.
• Provides neuroprotective effects in models of cerebral ischemia and neurodegeneration.
• Genetic variants in CYP epoxygenase genes and EPHX2 affect cardiovascular disease risk.
• Serves as a target for therapeutic development in cardiovascular and renal diseases.
• Plays a role in drug metabolism and drug-drug interactions involving CYP enzymes.
• Contributes to the resolution of inflammation through epoxy-fatty acid signaling.
What Happens During epoxygenase P450 pathway?
Arachidonic acid release and availability
In simple terms: Arachidonic acid is freed from cell membranes to become available for conversion.
Arachidonic acid is liberated from membrane phospholipids by phospholipase A2 and serves as the substrate for the epoxygenase P450 pathway. The availability of free arachidonic acid is a rate-limiting factor for EET production.
Epoxygenation by cytochrome P450 enzymes
In simple terms: CYP enzymes add an oxygen atom to arachidonic acid to create EETs.
Cytochrome P450 epoxygenases, primarily CYP2C and CYP2J isoforms, catalyze the insertion of an oxygen atom into one of the double bonds of arachidonic acid, generating four regioisomeric epoxyeicosatrienoic acids (5,6-, 8,9-, 11,12-, and 14,15-EET). These enzymes are expressed in various tissues including liver, kidney, heart, and endothelium.
Hydrolysis of EETs to DHETs
In simple terms: EETs are broken down into less active DHETs by soluble epoxide hydrolase.
Soluble epoxide hydrolase (sEH, encoded by EPHX2) hydrolyzes EETs to their corresponding dihydroxyeicosatrienoic acids (DHETs), which are generally less biologically active. This step is a key regulatory point that determines the half-life and activity of EETs.
Biological actions of EETs and DHETs
In simple terms: EETs act as signaling molecules that affect blood vessels, inflammation, and cell growth.
EETs exert vasodilatory, anti-inflammatory, and pro-angiogenic effects by activating signaling pathways such as BKCa channels, PPARs, and MAP kinases. DHETs are largely inactive but can be further metabolized or excreted.
Regulation of the pathway
In simple terms: The pathway is controlled by the levels and activity of CYP enzymes and sEH.
The epoxygenase P450 pathway is regulated at multiple levels, including transcriptional control of CYP epoxygenase genes, post-translational modifications, and the activity of soluble epoxide hydrolase. Genetic polymorphisms in CYP2C and EPHX2 influence enzyme activity and disease risk.
Key Genes Involved in GO:0019373 epoxygenase P450 pathway
The following genes encode key enzymes and regulators of the epoxygenase P450 pathway, and their experimental manipulation is central to understanding the pathway's role in health and disease.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP2C8 | Epoxygenase producing EETs from arachidonic acid | Genetic variants linked to cardiovascular risk and drug metabolism |
| CYP2C9 | Epoxygenase producing EETs | Polymorphisms affect enzyme activity and disease associations |
| CYP2C19 | Epoxygenase contributing to EET formation | Variants influence cardiovascular outcomes |
| CYP2J2 | Major epoxygenase in cardiovascular tissues | Overexpression protects against ischemia-reperfusion injury |
| EPHX2 | Soluble epoxide hydrolase degrading EETs to DHETs | Inhibition increases EET levels and is therapeutic target |
| PLA2G4A | Phospholipase A2 releasing arachidonic acid | Provides substrate for the pathway |
| PTGS2 | Cyclooxygenase-2 competing for arachidonic acid | Cross-talk with epoxygenase pathway |
| ALOX5 | Lipoxygenase competing for arachidonic acid | Alternative pathway affecting EET synthesis |
| CYP4A11 | Omega-hydroxylase with minor epoxygenase activity | Contributes to arachidonic acid metabolism |
| CYP4F2 | Omega-hydroxylase metabolizing EETs | Influences EET degradation |
| PPARA | Nuclear receptor regulating lipid metabolism | Modulates CYP epoxygenase expression |
| PPARG | Nuclear receptor mediating EET effects | EETs activate PPARgamma |
| KCNMA1 | BKCa channel subunit mediating EET vasodilation | Target of EET signaling |
| MAPK1 | MAP kinase involved in EET signaling | EETs activate MAPK pathways |
| MAPK3 | MAP kinase involved in EET signaling | EETs activate MAPK pathways |
| VEGFA | Vascular endothelial growth factor | EETs promote angiogenesis via VEGF |
| EDN1 | Endothelin-1 vasoconstrictor | Counteracts EET vasodilation |
How Is epoxygenase P450 pathway Regulated?
The epoxygenase P450 pathway is regulated by the expression levels and catalytic activities of cytochrome P450 epoxygenases and soluble epoxide hydrolase. Transcriptional regulation of CYP2C and CYP2J genes can be influenced by nuclear receptors such as PPARalpha and CAR. Post-translational modifications and protein-protein interactions also modulate enzyme activity. Additionally, genetic polymorphisms in CYP2C8, CYP2C9, and EPHX2 significantly affect pathway flux and have been associated with cardiovascular disease risk. The balance between EET formation and degradation by sEH is a critical determinant of EET bioavailability.
epoxygenase P450 pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP2C8 | Cardiovascular disease risk | Knockout or overexpression in endothelial cells |
| CYP2J2 | Ischemia-reperfusion injury, neuroprotection | Transgenic overexpression in mouse models |
| EPHX2 | Hypertension, cardiovascular toxicity | Knockout mice or sEH inhibitors |
| CYP2C9 | Drug metabolism and cardiovascular risk | Point mutation knock-in models |
| CYP2C19 | Cardiovascular outcomes | Knockout cell models |
Cardiovascular disease
Genetic variation in the cytochrome P450 epoxygenase pathway, including polymorphisms in CYP2C8, CYP2C9, and EPHX2, has been associated with altered risk of hypertension, coronary artery disease, and stroke. EETs promote vasodilation and reduce inflammation, and their degradation by sEH contributes to endothelial dysfunction. Inhibition of sEH to elevate EET levels is a promising therapeutic strategy for cardiovascular and renal diseases.
Cancer
The epoxygenase P450 pathway is implicated in cancer biology, where EETs can promote tumor growth and metastasis through effects on angiogenesis, cell proliferation, and apoptosis. In metastatic breast cancer, inhibition of the cytochrome P450 epoxygenase pathway has been shown to potentiate the therapeutic efficacy of paclitaxel, suggesting that pathway modulation may improve chemotherapy outcomes.
Neuroprotection and neurological disorders
Epoxyeicosatrienoic acids (EETs) exhibit neuroprotective effects in models of cerebral ischemia, traumatic brain injury, and neurodegeneration. These effects are mediated through anti-inflammatory, anti-apoptotic, and vasodilatory mechanisms, making the epoxygenase P450 pathway a potential target for neuroprotective therapies.
Endothelial-to-mesenchymal transition and cardiotoxicity
Inhibition of cytochrome P450 epoxygenase promotes endothelial-to-mesenchymal transition and exacerbates doxorubicin-induced cardiovascular toxicity, highlighting the pathway's protective role in maintaining endothelial integrity.
From epoxygenase P450 pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CYP2J2 affect EET production and vascular function? | CYP2J2 knockout cell line or mouse model |
| How do cardiovascular disease-associated polymorphisms in CYP2C9 alter enzyme activity? | Point mutation knock-in of CYP2C9 variants |
| Can overexpression of CYP2C8 protect against endothelial dysfunction? | CYP2C8 overexpression in endothelial cells |
| What is the effect of EPHX2 inhibition on EET levels and inflammation? | EPHX2 knockout or sEH inhibitor treatment |
| Does a tagged CYP2J2 knock-in reveal subcellular localization? | Tagged knock-in of CYP2J2 in cell lines |
| How does CYP2C19 knockout affect drug metabolism and EET synthesis? | CYP2C19 knockout hepatocyte-like cells |
How to Study the epoxygenase P450 pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS lipidomics | EET and DHET levels | Quantifying pathway flux in cells and tissues |
| qRT-PCR | mRNA expression of CYP genes | Assessing transcriptional regulation |
| RNA-seq | Global gene expression changes | Identifying pathway cross-talk |
| Western blot | Protein levels of CYP enzymes and sEH | Validating knockout or overexpression |
| Enzyme activity assay | Epoxygenase catalytic activity | Measuring EET production in vitro |
| CRISPR knockout | Loss-of-function phenotypes | Determining gene necessity |
| CRISPR knock-in | Tagged or mutant protein expression | Studying localization and function |
| Immunofluorescence | Subcellular localization of CYP enzymes | Visualizing pathway components |
Lipidomics and mass spectrometry
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for quantifying EETs and DHETs in biological samples, allowing researchers to measure pathway flux and the effects of genetic or pharmacological interventions.
Gene expression analysis
Quantitative RT-PCR and RNA-seq are used to measure mRNA levels of CYP epoxygenases and EPHX2 in tissues and cell models, providing insights into transcriptional regulation of the pathway.
Enzyme activity assays
In vitro assays using recombinant CYP enzymes or microsomal fractions can measure epoxygenase activity by incubating with arachidonic acid and detecting EET products via LC-MS/MS or fluorescence-based methods.
CRISPR-based genetic models
CRISPR-Cas9 knockout, knock-in, and point mutation models enable precise manipulation of CYP epoxygenase genes and EPHX2 to study their causal roles in disease phenotypes and pathway regulation.
How CRISPR Can Be Used to Study GO:0019373 epoxygenase P450 pathway
Knockout
CRISPR-Cas9 knockout of CYP epoxygenase genes (e.g., CYP2J2, CYP2C8) or EPHX2 allows researchers to abolish enzyme function and assess the consequences for EET production, vascular tone, and disease phenotypes. Knockout cell models are essential for establishing causality in the epoxygenase P450 pathway.
Point Mutation
Introducing disease-associated point mutations (e.g., in CYP2C9 or EPHX2) via CRISPR base editing or homology-directed repair enables functional analysis of genetic variants on enzyme activity and pathway flux.
Knock-in
Knock-in of tagged CYP epoxygenases (e.g., GFP or HA tags) facilitates real-time imaging and proteomic analysis of enzyme localization and interactions within the pathway.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of CYP2J2 or CYP2C8 can elevate EET levels and protect against endothelial dysfunction or ischemia-reperfusion injury, providing gain-of-function evidence for therapeutic potential.
How EDITGENE Supports epoxygenase P450 pathway Research
Researchers studying epoxygenase P450 pathway-related genes often need to determine whether a candidate gene is causally involved in EET production, vascular function, or disease progression. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for epoxygenase P450 pathway research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CYP2E1 Knockout HEK293 Cell Line | EDJ-KQ958 | Human | 1571 | Details Get a Quote |
| CYP1B1 Knockout HEK293 Cell Line | EDJ-KQ2285 | Human | 1545 | Details Get a Quote |
| CYP2C9 Knockout HEK293 Cell Line | EDJ-KQ2527 | Human | 1559 | Details Get a Quote |
| CYP2S1 Knockout HEK293 Cell Line | EDJ-KQ2870 | Human | 29785 | Details Get a Quote |
| CYP2A6 Knockout HEK293 Cell Line | EDJ-KQ3586 | Human | 1548 | Details Get a Quote |
| CYP2F1 Knockout HEK293 Cell Line | EDJ-KQ3671 | Human | 1572 | Details Get a Quote |
| CYP2C19 Knockout HEK293 Cell Line | EDJ-KQ3879 | Human | 1557 | Details Get a Quote |
| CYP1A1 Knockout HEK293 Cell Line | EDJ-KQ3897 | Human | 1543 | Details Get a Quote |
| CYP2A7 Knockout HEK293 Cell Line | EDJ-KQ4395 | Human | 1549 | Details Get a Quote |
| CYP2A13 Knockout HEK293 Cell Line | EDJ-KQ4396 | Human | 1553 | Details Get a Quote |
| CYP2B6 Knockout HEK293 Cell Line | EDJ-KQ4397 | Human | 1555 | Details Get a Quote |
| CYP2C8 Knockout HEK293 Cell Line | EDJ-KQ4398 | Human | 1558 | Details Get a Quote |
| CYP1A2 Knockout HEK293 Cell Line | EDJ-KQ4399 | Human | 1544 | Details Get a Quote |
| CYP2C18 Knockout HEK293 Cell Line | EDJ-KQ4403 | Human | 1562 | Details Get a Quote |
| CYP2J2 Knockout HEK293 Cell Line | EDJ-KQ4405 | Human | 1573 | Details Get a Quote |
Displaying Records 1 To 15 Of 72 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About epoxygenase P450 pathway
What is the epoxygenase P450 pathway?
The epoxygenase P450 pathway (GO:0019373) is a biological process in which cytochrome P450 enzymes convert arachidonic acid into epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids (DHETs).
What genes are involved in the epoxygenase P450 pathway?
Key genes include CYP2C8, CYP2C9, CYP2C19, CYP2J2, and EPHX2, which encode epoxygenases and soluble epoxide hydrolase, respectively.
What are epoxyeicosatrienoic acids (EETs)?
EETs are lipid mediators produced by cytochrome P450 epoxygenases from arachidonic acid; they regulate vascular tone, inflammation, and cell growth.
How is the epoxygenase P450 pathway regulated?
The pathway is regulated by the expression and activity of CYP epoxygenases and soluble epoxide hydrolase, as well as genetic polymorphisms in these genes.
What diseases are associated with the epoxygenase P450 pathway?
It has been linked to cardiovascular disease, hypertension, cancer, and neurological disorders.
What is the role of soluble epoxide hydrolase in this pathway?
Soluble epoxide hydrolase (EPHX2) degrades EETs to less active DHETs, thereby regulating the biological effects of the pathway.
Can CRISPR be used to study the epoxygenase P450 pathway?
Yes, CRISPR knockout, knock-in, and point mutation models are powerful tools to dissect gene function and disease mechanisms in this pathway.
What are the therapeutic implications of targeting the epoxygenase P450 pathway?
Modulating the pathway, such as inhibiting sEH to increase EET levels, is a promising strategy for cardiovascular, renal, and neuroprotective therapies.
Which cytochrome P450 enzymes are most important for EET production?
CYP2C and CYP2J subfamily enzymes are the primary epoxygenases responsible for EET synthesis.
How can I measure epoxygenase P450 pathway activity?
LC-MS/MS lipidomics is the most reliable method to quantify EETs and DHETs, reflecting pathway activity.
Conclusion
The epoxygenase P450 pathway (GO:0019373) is a vital metabolic route that converts arachidonic acid into bioactive EETs and DHETs, with profound implications for cardiovascular, renal, and neurological health. Genetic and pharmacological studies continue to uncover its role in disease, and CRISPR-based models offer powerful tools to dissect its mechanisms. Targeting this pathway holds promise for novel therapeutics in cardiovascular disease, cancer, and neuroprotection.
References
- 1. Spector AA et al.. 2015. Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.. Biochim Biophys Acta 1851(4):356-65 PMID: 25093613
- 2. Spector AA. 2009. Arachidonic acid cytochrome P450 epoxygenase pathway.. J Lipid Res 50 Suppl(Suppl):S52-6 PMID: 18952572
- 3. Theken KN et al.. 2007. Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk.. Pharmacogenomics 8(10):1369-83 PMID: 17979511
- 4. Dhulkifle H et al.. 2024. Inhibition of cytochrome P450 epoxygenase promotes endothelium-to-mesenchymal transition and exacerbates doxorubicin-induced cardiovascular toxicity.. Mol Biol Rep 51(1):859 PMID: 39066934
- 5. Gomes RN et al.. 2018. Eicosanoids and cancer.. Clinics (Sao Paulo) 73(suppl 1):e530s PMID: 30133566
- 6. Manhas D et al.. 2025. Crocetin Impairs the Cytochrome P450 Epoxygenase Pathway toward Potentiating the Therapeutic Efficacy of Paclitaxel in Metastatic Breast Cancer.. ACS Omega 10(40):46542-46553 PMID: 41114181
- 7. Wang L et al.. 2018. Neuroprotective effects of epoxyeicosatrienoic acids.. Prostaglandins Other Lipid Mediat 138:9-14 PMID: 30031209
- 8. Imig JD. 2018. Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics.. Pharmacol Ther 192:1-19 PMID: 29964123
